WO2002072557A1

WO2002072557A1 - Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients

Info

Publication number: WO2002072557A1
Application number: PCT/EP2002/001918
Authority: WO
Inventors: Volkmar Wehner; Hans Ulrich Stilz; Klaus Burger; Alexander Golubev; Sergej Ossipov
Original assignee: Aventis Pharma Deutschland Gmbh
Priority date: 2001-03-10
Filing date: 2002-02-23
Publication date: 2002-09-19
Also published as: JP4340065B2; EP1381595A1; DE60221660T2; JP2004519491A; US20020183374A1; US6794517B2; DE10111876A1; DE60221660D1; EP1381595B1; ATE369345T1

Abstract

The present invention relates to hydantoins of formula (I), in which R is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative which is obtained formally by removing an NH2 group from an amino carboxylic acid or an amino carboxylic acid or an amino carboxylic acid derivative, to the preparation thereof and to the use thereof as intermediates, in particular for preparing pharmaceutically active ingredients.

Description

Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients

The present invention relates to hydantoins of the formula I,

in which R is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative which is obtained formally by removing an NH₂ group from an amino carboxylic acid or an amino carboxylic acid derivative, to the preparation thereof and to the use thereof as intermediates, in particular for preparing pharmaceutically active ingredients.

Various patent documents, for example EP-A-903353, EP-A-905139, EP-A-918059^' and WO-A-99/60015, describe pharmaceutically active substituted hydantoins which are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group, and are suitable, for example, for treating disorders such as rheumatoid arthritis, asthma, allergies, multiple sclerosis or atherosclerosis. Said documents disclose various methods for synthesizing the hydantoins starting from different starting compounds and proceeding via different intermediates. In these methods it is possible, for example, first to assemble a hydantoin intermediate in which the ring nitrogen atoms do not carry substituents, i. e. they carry hydrogen atoms, and then to introduce onto the nitrogen atoms of the hydantoin ring substituents which can subsequently be modified. Just so it is possible for substituents to be bonded to nitrogen atoms in starting compounds when assembling a hydantoin intermediate, which substituents then appear in the hydantoin intermediate. Certain hydantoins as intermediates for preparing pharmaceutically active ingredients are described in WO-A-96/33976. In particular for preparing a group of certain pharmaceutically active hydantoins (= 2,5-dioxoimidazolidines) which carry two trifluoromethyl groups as substituents on the carbon atom in the 4 position and are distinguished by a particularly favorable profile of properties, it has now proved advantageous to employ the hydantoins of the formula I, which have not previously been described, as intermediates.

A subject of the present invention therefore are the hydantoins of the formula I

in which R is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative which is obtained formally by removing an NH₂ group from an amino carboxylic acid or an amino carboxylic acid derivative, and the salts thereof. The compounds of the formula I thus contain in the residue R at least one carboxylic acid group COOH or a derivative thereof or a salt thereof.

Amino carboxylic acid derivatives mean compounds which are obtained formally from the relevant amino carboxylic acid by converting one or more carboxylic acid groups into other groups which are directly related to the carboxylic acid group, for example ester groups, amide groups, nitrile groups, aldehyde groups or hydroxymethyl groups, in particular ester groups. Examples of ester groups are (CrCe)-alkyl esters such as methyl esters, ethyl esters, propyl esters such as n-propyl esters and isopropyl esters, butyl esters such as n-butyl esters, isobutyl esters, sec-butyl esters and tert-butyl esters, pentyl esters and hexyl esters, or phenyl-(CrC₄)-alkyl esters such as benzyl esters. Examples of amide groups are unsubstituted amides (CONH₂), N-(Cι-C₄)-alkylamides and N,N-di-((C C₄)-alkyl)amides such as N-methylamides and N,N-dimethylamides, N-methoxy-N-methylamides and N-benzylamides.

The amino carboxylic acid or the amino carboxylic acid derivative of the formula H₂N-R from which the residue R in the formula I is derived may be a natural or unnatural amino carboxylic acid or a derivative of a natural or unnatural amino carboxylic acid. Besides one or more carboxylic acid groups or derivatives of carboxylic acid groups such as ester groups, amide groups, nitrile groups, aldehyde groups or hydroxymethyl groups, the residue R or the amino carboxylic acid or the amino carboxylic acid derivative from which the residue R is derived may contain one or more other functional groups. All functional groups and carboxylic acid groups and derivatives of carboxylic acid groups may be present in protected form. Suitable protective groups such as, for example, urethane protective groups, carboxylic acid protective groups and side-chain protective groups are described in Hubbuch, Kontakte (Merck) 1979, No. 3, pages 14 to 23, and in Bϋllesbach, Kontakte (Merck) 1980, No. 1 , pages 23 to 35. As examples the following may be mentioned: Aloe, Pyoc, Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO₂), Z(Hal_n), Bobz, Iboc, Adpoc, Mboc, Acm, tert-butyl, OBzl, ONbzl, OMbzl, Bzl, Mob, Pic, Trt and acetal groups and ketal groups, for example geminal methoxy groups or ethoxy groups or ethylene-1 ,2-dioxy groups, as protective groups for aldehyde groups and keto groups. Examples of functional groups which may be present in the residue R besides derivatives of carboxylic acid groups are hydroxyl, (CrC₄)-alkoxy, ((C₁-C₄)- alkyl)carbonyloxy, benzyloxy, oxo, amino, ((Cι-C₄)-alkyl)carbonylamino such as acetylamino or isobutyrylamino, ((CrC₄)-alkoxy)carbonylamino such as tert- butoxycarbonylamino, benzyloxycarbonylamino, 9-fluorenyImethyloxycarbonylamino, mercapto, (CrC4)-alkylmercapto, amidino, guanidino, etc., and protected forms of these groups.

Compounds of the formula I which contain one or more basic groups, for example amino groups, guanidino groups or basic nitrogen heterocycles, may be present in the form of acid addition salts including salts with inorganic acids such as, for example, hydrogen chloride, hydrogen bromide, sulfuric acid or phosphoric acid, and salts with organic carboxylic acids and sulfonic acids, such as, for example, acetic acid, trifluoroacetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formula I which contain acidic groups, for example one or more carboxylic acid groups, may, for example, be present in the form of metal salts, for example alkali metal salts or alkaline earth metal salts, such as lithium salts, sodium salts, potassium salts, magnesium salts or calcium salts, or in the form of ammonium salts including, for example, salts with quaternary ammonium ions and acid addition salts with ammonia and organic amines such as, for example, ethylamine, triethylamine, ethanolamine, tris(2-hydroxyethyl)amine, α,α,α-tris(hydroxymethyl)methylamine or amino acids. Compounds of the formula I which contain both acidic groups and basic groups may also be present in the form of inner salts or betaines (zwitterions) which are likewise encompassed by the present invention. Salts may be obtained from the compounds of the formula I by conventional methods known to a person skilled in the art, for example by combining with an organic or inorganic acid or base in a solvent or diluent, or by anion exchange or cation exchange from other salts.

The present invention encompasses the compounds of the formula I in all their tautomeric forms. The invention further encompasses solvates of compounds of the formula I, for example hydrates and adducts with alcohols.

The present invention encompasses the compounds of the formula I in all stereoisomeric forms, for example enantiomers and diastereomers, and mixtures of two or more stereoisomeric forms, for example mixtures of enantiomers and/or diastereomers, in all ratios. If the compounds of the formula I contain one or more asymmetric centers, these may have, independently of one another, the S configuration or R configuration. The invention thus relates to enantiomers in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios. The invention likewise relates to diastereomers in diastereomerically pure form and in the form of mixtures of two or more diastereomers in all ratios. If a cis/trans isomerism is possible in the compounds of the formula I, for example if a double bond or a substituted cycloalkyl residue is present, the invention relates both to the cis form and to the trans form, or the Z form and the E form, and mixtures of these forms in all ratios. These statements apply correspondingly to the amino carboxylic acids and the amino carboxylic acid derivatives of the formula H₂N-R from which the residue R is derived and which may be present in all stereochemical forms, for example in the D form, the L form or the DL form. Individual stereoisomers can be prepared by using stereochemically pure starting materials in the synthesis, by stereoselective synthesis or by separating a mixture by conventional methods, for example by chromatography or crystallization, in the case of enantiomers for example by chromatography on chiral phases. A derivatization may take place where appropriate before a separation of stereoisomers. The separation of a stereoisomer mixture may take place at the stage of compounds of the formula I or at the stage of a starting material or of an intermediate during the synthesis.

The following may be mentioned as examples of amino carboxylic acids from which or from whose derivatives the residue R may be derived (cf. Houben-Weyl, Methoden der organischen Chemie, volume 15/1 and 15/2, Georg Thieme Verlag, Stuttgart, 1974):

Aad, Abu, yAbu, ABz, 2ABz, εAca, Ach, Acp, Adpd, Ahb, Aib, βAib, Ala, βAla, ΔAIa, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Bph, Can, Cit, Cys, Daad, Dab, Dadd, Dap, Dapm, Dasu, Dpa, Fel, Gin, Glu, Gly, hAla, hArg, hCys, hGln, hGlu, His, hlle, hLeu, hLys, hMet, hPhe, hSer, hThr, hTrp, hTyr, Hyl, lie, Ise, Iva, Kyn, Lant, Lcn, Leu, Lys, βLys, ΔLys, Met, nArg, Nle, Nva, Oly, Orn, Pan, Pen, Phe, Phg, Pse, Pya, Pza, Ros, Sec, Sem, Ser, Thi, βThi, Thr, Thy, Thx, Tie, Tly, Trp, Trta, Tyr, Val, tert-butylglycine (Tbg), neopentylglycine (Npg), cyclohexylglycine (Chg), cyclohexylalanine (Cha), 2-thienylalanine (Thia), 2,2-diphenylaminoacetic acid, 2-(p-tolyl)-2-phenylaminoacetic acid, 2-(p-chlorophenyl)aminoacetic acid, 3-aminobenzoic acid. The residue R in the formula I is preferably derived from an α-amino carboxylic acid or an α-amino carboxylic acid derivative or a salt thereof, from a β-amino carboxylic acid or a β-amino carboxylic acid derivative or a salt thereof, from a -annino carboxylic acid or a κ-amino carboxylic acid derivative or a salt thereof, or from an aromatic amino carboxylic acid or an aromatic carboxylic acid derivative or a salt thereof. The residue R in the formula I is particularly preferably derived from an α-amino carboxylic acid or an α-amino carboxylic acid derivative or a salt thereof or from a β-amino carboxylic acid or a β-amino carboxylic acid derivative or a salt thereof. The residue R in the formula I is very particularly preferably derived from an α-amino carboxylic acid or an α-amino carboxylic acid derivative or a salt thereof. α-Amino carboxylic acids mean compounds which contain at least one amino group and at least one carboxylic acid group, of which one amino group and one carboxylic acid group are separated from one another by one carbon atom. β-Amino carboxylic acids mean compounds which contain at least one amino group and at least one carboxylic acid group, of which one amino group and one carboxylic acid group are separated from one another by a chain of two carbon atoms. -Amino carboxylic acids mean compounds which contain at least one amino group and at least one carboxylic acid group, of which one amino group and one carboxylic acid group are separated from one another by a chain of three carbon atoms. Aromatic amino carboxylic acids mean compounds which contain at least one amino group and at least one carboxylic acid group which are bonded to a carbocyclic or heterocyclic aromatic ring system.

In a preferred embodiment the present invention thus provides a compound of the formula la or a derivative or salt thereof, or a compound of the formula lb or a derivative or salt thereof, or a compound of the formula lc or a derivative or a salt thereof, or a compound of the formula Id or a derivative or a salt thereof, particularly preferably a compound of the formula la or a derivative or a salt thereof, or a compound of the formula lb or a derivative or a salt thereof, very particularly preferably a compound of the formula la or a derivative or a salt thereof. The residues C(R )(R²)COOH etc. bonded to a ring nitrogen atom which are present in the compounds of formulae la etc. are subgeneric embodiments of the residue R which is present in the compounds of the formula 1.

la lb

lc Id

In the compounds of the formulae la, lb and lc, R¹, R², R³, R⁴, R⁵ and R⁶ are, independently of one another, hydrogen, (CrC₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(Cι-C₄)-alkyl, (C₆-C₁₂)-aryl,

(C₆-Cι₂)-aryl-(C₁-C₄)-alkyl, heteroaryl or heteroaryl-(Cι-C₄)-alkyl. It is also possible for R¹ and R² together with the carbon atom carrying these groups or for R³ and R⁴ together with the carbon atom carrying these groups or for R⁵ and R⁶ together with the carbon atom carrying these groups to form a (C₃-C₇)-cycloalkane ring, or it is possible, for example, for R¹ and R³ together with the carbon atoms carrying these groups or for R³ and R⁵ together with the carbon atoms carrying these groups to form a (C₃-C₇)-cycloalkane ring. The groups representing R¹, R², R³, R⁴, R⁵ and R⁶ may be unsubstituted or be substituted by one or more identical or different substituents. The divalent residue Ar in the compounds of the formula Id is a divalent residue of a monocyclic or polycyclic aromatic ring system, for example of a monocyclic, bicyclic or tricyclic aromatic ring system, with 5 to 15 ring members including 5, 6, 8, 9, 10, 11 , 12, 13, 14 and 15 ring members, which can contain 1 , 2, 3 or 4 identical or different ring heteroatoms from the series nitrogen, oxygen and sulfur. The groups representing Ar may be unsubstituted or be substituted by one or more identical or different substituents.

Derivatives of the compounds of the formulae la, lb, lc and Id are, as explained above for the compounds of the formula I, compounds in which the carboxylic acid groups depicted in the formulae la, lb, lc and Id and/or other carboxylic acid groups present in the molecules are converted into other functional groups, for example ester groups, amide groups, nitrile groups, aldehyde groups or hydroxymethyl groups, in particular ester groups.

Alkyl groups, alkenyl groups and alkynyl groups may be straight-chain or branched. Examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl (= 1-methylethyl), n-butyl, sec-butyl (= 1-methylpropyl), isobutyl (= 2-methylpropyl), tert-butyl

(= 2,2-dimethylpropyl), n-pentyl, 1-methylbutyl, isopentyl, neopentyl, tert-pentyl, n-hexyl or isohexyl, and examples of alkenyl and alkynyl are vinyl, prop-2-enyl (allyl), prop-1-enyl, but-2-enyl, but-3-enyl, 3-methylbut-2-enyl, penta-2,4-dienyl, ethynyl, prop-2-ynyl (propargyl), prop-1-ynyl, but-2-ynyl and but-3-ynyl. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Examples of cycloalkylalkyl residues are cyclopropylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 3-cyclopropylpropyl, 4-cyclopropylbutyl, cyclobutylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, 1-cyclopentylethyl, 2-cyclopentylethyl, 3-cyclopentylpropyl, cyclohexyl methyl, 1-cyclohexyIethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, cycloheptylmethyl, 2-cycloheptylethyl.

Examples of aryl groups are phenyl, 1-naphthyl, 2-naphthyl, 2-biphenylyl, 3-biphenylyl and 4-biphenylyl, in particular phenyl. Heteroaryl groups are preferably derived from monocyclic 5-membered or 6-membered aromatic ring systems or bicyclic 9-membered or 10-membered aromatic ring systems which contain 1 , 2 or 3 identical or different heteroatoms from the series nitrogen, oxygen and sulfur, in particular from monocyclic 5-membered or 6-membered aromatic ring systems. Examples of heteroaryl are, in particular, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, 1 ,3-oxazolyl, 1 ,2-oxazolyl, 1 ,3-thiazolyl, 1 ,2-thiazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, indoiyl, benzofuranyl, benzothienyl, benzimidazolyl, 1 ,3-benzoxazolyl, 1 ,3-benzothiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, etc. A heteroaryl residue may be bonded via any suitable position. For example, a thienyl residue may be present in the form of the 2-thienyl residue or 3-thienyl residue, a furyl residue may be present in the form of the 2-furyl residue or 3-furyl residue, a pyridyl residue may be present in the form of the 2-pyridyl residue, 3-pyridyl residue or 4-pyridyl residue. A residue derived from 1 ,3-thiazole or from imidazole may be bonded via the 2 position, the 4 position or the 5 position, a residue derived from quinoline via the 2 position, 3 position, 4 position, 5 position, 6 position, 7 position, 8 position. Examples of arylalkyl residues are benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, (l-naphthyl)methyl, (2-naphthyl)methyl, 1-(1-naphthyl)ethyl, 1-(2-naphthyl)ethyl, 2-(1-naphthyl)ethyl, 2-(2-naρhthyl)ethyl, (2-biphenylyl)methyl, (3-biphenylyl)methyI, (4-biphenylyl)methyl. Examples of heteroarylalkyl residues are (2-pyridyl)methyl, (3-pyridyl)methyl, (4-pyridyl )methyl, 2-(2-pyridyl)ethyl, 2-(3-pyridyl)ethyl, 2-(4-pyridyl)ethyl, (2-thienyl)methyl, (3-thienyl)methyl, 2-(2-thienyl)ethyl, 2-(3-thienyl)ethyl, (4-imidazolyl)methyl, (3-indolyl)methyl.

The above explanations on aryl groups and heteroaryl groups apply correspondingly to the divalent group Ar in the compounds of the formula Id which is derived from a carbocyclic or heterocyclic aromatic ring system. The residues Ar may, for example, be derived from the aromatic residues listed above. Examples of the divalent residue Ar are phenylene, biphenylylene (biphenyldiyl), naphthylene (naphthalenediyl), fluorenylene (fluorenediyl), anthracenediyl, thiophenediyl, furandiyl, pyrrolediyl, pyrazolediyl, imidazolediyl, thiazolediyl, pyridinediyl, pyridazinediyi, pyrimidinediyl, pyrazinediyl, indolediyl, benzothiophenediyl, quinolinediyl, isoquinolinediyl, carbazolediyl, phenothiazinediyl. The residue Ar may be bonded via any suitable positions of the aromatic ring system. For example, a phenylene residue may be a 1 ,2-, 1 ,3- or 1 ,4-phenylene residue, a naphthalenediyl residue may be a 1,2-, 1,3-, 1 ,4-, 1 ,5-, 1 ,6-, 1 ,7-, 1 ,8-, 2,3-, 2,6- or 2,7-naphthalenediyl residue, a thiophenediyl residue may be a 2,3-, 2,4-, 2,5- or 3,4-thiophenediyl residue, a pyridinediyl residue may be a 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-pyridinediyl residue.

The alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl groups representing R¹, R², R³, R⁴, R⁵ and R^δ may be unsubstituted or carry one or more, for example one, two, three or four, identical or different substituents, in the case of the cycloalkylalkyl, arylalkyl and heteroarylalkyl groups in particular in the cyclic moiety. Besides carboxylic acid groups (hydroxycarbonyl groups, carboxyl groups, COOH groups) and derivatives of carboxylic acid groups such as ester groups, for example ((Cι-C₆)-alkoxy)carbonyl groups, amide groups, for example CONH₂ groups, nitrile groups (cyano groups), aldehyde groups (CH(=O) groups) or hydroxymethyl groups (CH₂OH groups), possible substituents which may be present in R , R², R³, R⁴, R⁵ and R⁶ are, for example, halogen including fluorine and chlorine, trifluoromethyl, hydroxyl, (Cι-C )-alkoxy, benzyloxy, oxo, nitro, amino, ((Cι-C )-alkyl)carbonylamino, ((Cι-C )-alkoxy)carbonylamino,

9-fluorenylmethyloxycarbonylamino, benzyloxycarbonylamino, mercapto, (Cι-C )-alkylmercapto, amidino, guanidino, etc., it also being possible for the substituent groups to be present in protected form. Cycloalkyl groups, aryl groups and heteroaryl groups may also carry (Cι-G )-alkyl residues, for example methyl residues, as substituents. The substituents in substituted residues may be present in any suitable positions as long as the resulting compound is stable and suitable for the desired purpose. The substituent in monosubstituted phenyl residues may be present in the 2 position, the 3 position or the 4 position. The substituents in disubstituted phenyl residues may be present in the 2,3 position, 2,4 position, 2,5 position, 2,6 position, 3,4 position or 3,5 position. The above explanations apply correspondingly to the substituents which may be present in the residue Ar. Ar may, for example, be substituted by one, two, three or four identical or different substituents from the series COOH, ester groups such as ((Cι-C₆)-alkoxy)carbonyl, amide groups such as CONH₂, cyano, CH(=O), CH₂OH, (Cι-C₄)-alkyl, fluorine, chlorine, trifluoromethyl, hydroxyl, (Cι-C₄)-alkoxy, benzyloxy, nitro, amino,

((Cι-C )-alkyl)carbonylamino, ((C-ι-C₄)-alkoxy)carbonylamino, (Cι-C₄)-alkylmercapto, it also being possible for the substituent groups to be present in protected form. The R² group in the compounds of the formula la is preferably hydrogen or methyl. In the compounds of the formula lb preferably the R² and/or R³ and/or R⁴ groups are, independently of one another, hydrogen or methyl, or the R¹ and/or R² and/or R⁴ groups are, independently of one another, hydrogen or methyl. In the compounds of the formula lc preferably the R² and/or R³ and/or R⁴ and/or R⁵ and/or R⁶ groups are, independently of one another, hydrogen or methyl, or the R¹ and/or R² and/or R⁴ and/or R⁵ and/or R⁶ groups are, independently of one another, hydrogen or methyl, or the R¹ and/or R² and/or R³ and/or R⁴ and/or R⁶ groups are, independently of one another, hydrogen or methyl. The Ar group in the compounds of the formula Id is preferably a divalent residue of a 5-membered or 6-membered monocyclic aromatic ring system or of a 9-membered or 10-membered bicyclic aromatic ring system which can contain 1 or 2 identical or different ring heteroatoms from the series nitrogen, oxygen and sulfur.

The R² group in the compounds of the formula la is particularly preferably hydrogen. In the compounds of the formula lb particularly preferably the R², R³ and R⁴ groups are hydrogen or the R¹, R² and R⁴ groups are hydrogen. In the compounds of the formula lc particularly preferably the R², R³, R⁴, R⁵ and R⁶ groups are hydrogen or the R¹, R², R⁴, R⁵ and R⁶ groups are hydrogen or the R¹, R², R³, R⁴ and R⁶ groups are hydrogen. The Ar group in the compounds of the formula Id is particularly preferably a divalent residue of a 5-membered or 6-membered monocyclic aromatic ring system which can contain 1 or 2 identical or different ring heteroatoms from the series nitrogen, oxygen and sulfur, for example a phenylene residue or a thiophenediyl residue.

A very particularly preferred embodiment of the present invention provides a compound of the formula le or a derivative or salt thereof.

R¹ in the compounds of the formula le has the meanings indicated above and may be substituted as indicated above. Derivatives of compounds of the formula le mean, as explained above, compounds in which the carboxylic acid group depicted in the formula le, and/or other carboxylic acid groups present in the molecule, are converted into other functional groups, for example ester groups, amide groups, nitrile groups, aldehyde groups or hydroxymethyl groups, in particular ester groups.

The residue -CHR¹ -COOH in the compounds of the formula le is derived formally from an α-amino carboxylic acid of the formula H₂N-CHR¹-COOH by removal of the H₂N group. According to a usual way of viewing the R¹ residue in the compounds of the formula le and in the amino carboxylic acids of the formula H₂N-CHR -COOH, R¹ corresponds to the side chain of the α-amino carboxylic acid. Examples of such side chains and of the R¹ residue in the formula le are alkyl residues, for example the methyl, isopropyl and isobutyl side chains present in alanine, valine or leucine, the cyclopropylmethyl side chain present in β-cyclopropylalanine, the benzyl side chain present in phenylalanine, the phenyl side chain present in phenylglycine, the 4-aminobutyl side chain present in lysine or the hydroxycarbonylmethyl side chain present in aspartic acid. As explained above, functional groups in the side chain of the α-amino carboxylic acid from which the -CHR¹ -COOH residue in the compounds of the formula le may be derived may be present in protected form.

R¹ in the compounds of the formulae la, lb, lc and le is preferably hydrogen, (Cr C₆)-alkyl, (C₃-C₇)-cycloalkyl or (C₃-C )-cycloalkyl-(Cι-C4)-alkyl, particularly preferably (Cι-C₆)-alkyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyl-(C₁-C₄)-alkyl, very particularly preferably (C C₆)-alkyl or (C₃-C₆)-cycloalkyl-(Cι-C₂)-alkyl, in particular (C₃-C₅)-alkyl or (C₃-C₆)-cycIoalkyl-(CrC₂)-alkyl. Examples of specifically preferred meanings of R¹, in particular in the compounds of the formula le, are isopropyl ((CH₃)₂CH-), isobutyl ((CH₃)₂CH-CH₂-), neopentyl ((CH₃)₃C-CH₂-), cyclopropylmethyl (cycloC₃H₅-CH₂-), cyclobutylmethyl (cycloC₄H₇-CH₂-) and cyclopentylmethyl (cycloC₅H₉-CH₂-), specifically isobutyl and cyclopropylmethyl. The asymmetric carbon atom to which the R¹ group is bonded in compounds of the formula le preferably has the S configuration.

Compounds of the formula I of the invention can be prepared by reacting the compound of the formula II with a compound of the formula III.

The R' residue in the formula III has the meanings stated above for the R residue in formula I, but free carboxylic acid groups are present in the compounds of the formula III in esterified form, for example in the form of the (C C₆)-alkyl esters or benzyl esters, such as in the form of the tert-butyl esters, and other functional groups, for example aldehyde groups or hydroxymethyl groups, may be or must be present in protected form or in the form of precursors, as already explained above for compounds of the formula I. Examples of precursors which may be mentioned are nitro groups which can be converted in a later step into amino groups by reduction, or nitrile groups which can be converted in a later step into aminomethyl groups by reduction or into amide groups or carboxylic acid groups by hydrolysis. Such protective group techniques and synthetic strategies for avoiding unwanted reactions taking place or for preventing side reactions are familiar to a person skilled in the art. A subject of the present invention also is a process for preparing the compounds of the formula I, which comprises reacting the compound of the formula II with a compound of the formula III. In the compounds of the formula I obtained as direct products of the reaction of compounds of the formulae II and III it is subsequently possible to modify functional groups. For example, ester groups can be converted by standard methods into carboxylic acid groups, for example by hydrolysis with an acid such as hydrochloric acid or, in the case of tert-butyl esters, by treating with trifluoroacetic acid. It is also possible for an ester group of a particular type, for example a tert-butyl ester, to be converted selectively into a carboxylic acid group, and an ester group of another type, for example an ethyl ester, to be left unchanged. A further example which may be mentioned is the liberation of protected aldehyde groups or hydroxymethyl groups. Depending on the intended use, it may be advantageous for further protective groups in the resulting compounds of the formula I to be removed before further processing by standard methods and for the protected functional groups thus to be liberated again, or for protective groups initially to be retained on functional groups and be removed only after the further processing.

The reaction of compounds of the formulae II and III is advantageously carried out in an inert solvent such as a hydrocarbon or ether, for example benzene or toluene, generally at temperatures from about 20°C to about 80°C. For example, after the reactants have been combined, the reaction mixture is heated to a temperature of from about 40°C to about 80°C, for example to about 60°C. For workup, the volatile components can be removed in vacuo and the crude product of the formula I can be purified by standard methods, for example by chromatography.

The 2-tert-butoxy-4,4-bis(trifluoromethyl)-1 ,3-oxazabuta-1 ,3-diene of the formula II can be obtained by the method described by Steglich et al., Chemische Berichte 107 (1974), 1488. The starting materials are tert-butyl carbamate ((CH₃)₃C-O-CO-NH₂) and anhydrous hexafluoroacetone which are initially reacted, for example in a solvent such as dichloromethane at room temperature, to give 2-tert-butoxycarbonylamino- 2-hydroxy-1 ,1 ,1 ,3,3,3-hexafluoropropane. This intermediate is then converted, for example in a solvent such as diethyl ether at temperatures from about 0°C to about 10°C, by treatment with trifluoroacetic anhydride in the presence of a base such as quinoline into the compound of the formula II, which can be purified by distillation. Details of the preparation are described below.

The isocyanides (isonitriles) of the formula III can be obtained by standard methods known to a person skilled in the art from the respective amino carboxylic acid derivatives of the formula H₂N-R' in which R' has the meaning indicated for formula III. The amino carboxylic acid derivative of the formula H₂N-R' is advantageously first converted by reaction with a reactive formic ester, for example cyanomethyl formate, into the N-formylamino carboxylic acid derivative of the formula HC(=O)-NH-R' in which R' has the meaning indicated for formula III. This N-formyl compound is then converted, for example by reaction with phosgene or a phosgene equivalent such as diphosgene or triphosgene, in the presence of a tertiary amine such as triethylamine in a solvent such as dichloromethane at temperatures from about -40°C to about 0°C into the isocyanide of the formula III.

The compounds of the formula I are valuable intermediates for preparing pharmaceutically active compounds which comprise a 2,5-dioxo-4,4- bis(trifluoromethyl)imidazolidine ring whose 1 position is bonded to a structural element which is obtained formally from an amino carboxylic acid or an amino carboxylic acid derivative by removal of an amino group, and whose 3 position may optionally carry an additional substituent. Examples of such pharmaceutically active compounds are antagonists of the integrin VLA-4 as are described, for example, in EP-A-918059 or WO-A-99/60015 and can be represented by formula IV

in which the divalent residue -D-CO- is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative which is obtained formally by removal of an NH₂ group from an amino carboxylic acid and by removal of the hydroxyl group from the carboxylic acid group, the residue -NH-E is the residue of an amino compound such as, for example, of an amino acid, of an amino acid ester, of a dipeptide or of an amino alcohol, which is obtained formally by removal of a hydrogen atom from an amino group, and R¹⁰ is, for example, an optionally substituted arylalkyl residue, for example a substituted benzyl residue.

Compounds of the formula I can be converted into a pharmaceutically active compound, for example, by first introducing a substituent on the nitrogen atom in the 3 position, for example by an alkylation with a halogen compound such as a substituted benzyl chloride or benzyl bromide in the presence of a base, and subsequently, where appropriate after removal of protective groups, reacting a functional group present in the R residue, for example a carboxylic acid group or a derivative thereof such as an ester group, amide group, nitrile group, aldehyde group or hydroxymethyl group, with a further synthon. A compound of the formula IV is preferably synthesized by employing a compound of the formula I in which R contains a carboxylic acid group, and which is reacted under standard conditions in the presence of a condensing reagent as is known from peptide chemistry for generating amide bonds, for example TOTU or a carbodiimide such as N,N'- dicyclohexylcarbodiimide, with a compound of the formula H₂N-E, for example an amino acid ester or an amino alcohol. An example of such a reaction to give a pharmaceutically active ingredient is described below.

Subjects of the present invention also are the use of the compounds of the formula I as intermediates, in particular for preparing pharmaceutically active ingredients, and a process for preparing pharmaceutically active ingredients which comprise a 2,5-dioxo-4,4-bis(trifluoromethyl)imidazolidine ring whose 1 position is bonded to a synthon which is obtained formally from an amino carboxylic acid or an amino carboxylic acid derivative by removal of an amino group, and whose 3 position may optionally carry an additional substituent, which process comprises reacting a functional group which is present or liberated in the residue R in the formula I, for example the carboxylic acid group or a derivative thereof which is present in the residue R, with a further synthon and optionally introducing an additional substituent in the 3 position.

Examples

Example 1 tert-Butyl (S)-2-(4,4-bis(trifluoromethyl)-2,5-dioxoimidazolidin-1-yl)-2- (2-methylpropyl)acetate

1a) 2-tert-Butoxy-4,4-bis(trifluoromethyl)-1 ,3-oxazabuta-1 ,3-diene

The compound was prepared in analogy to W. Steglich et al., Chem. Ber. 107 (1974), 1488-1498. Anhydrous hexafluoroacetone (HFA) was prepared by adding HFA trihydrate dropwise to concentrated sulfuric acid heated to 80°C. The resulting gas was once more washed with concentrated sulfuric acid and then passed into the gas space of the reaction flask. A reflux condenser packed with acetone/dry ice was fitted on the gas outlet of the flask.

As described above, a solution of 20 g (170 mmol) of tert-butyl carbamate in 150 ml of dichloromethane was reacted with anhydrous gaseous HFA until the reaction solution was saturated. The solvent was removed in vacuo, and the resulting crude 2-tert-butoxycarbonylamino-2-hydroxy-1 ₎1₎1 ,3,3,3-hexafluoropropane (yield: 48.3 g, 100%) was used in the subsequent reaction.

13.6 g of trifluoroacetic anhydride, and subsequently 5 drops of quinoline, were added dropwise to a solution of 50.05 g (176 mmol) of 2-tert-butoxycarbonylamino- 2-hydroxy-1 ,1 ,1 ,3,3,3-hexafluoropropane in 300 ml of diethyl ether at 0°C. After stirring at 0°C for 10 minutes, a further 27.2 g of trifluoroacetic anhydride were added dropwise. The reaction mixture was stirred at 0°C (external temperature) for 30 minutes, during which the internal temperature of the mixture rose to 8-10°C. After cooling to 0°C, 50.01 g (388 mmol) of quinoline were added, whereupon the trifluoroacetic acid salt of the quinoline started to crystallize. After stirring at 0°C for 2 hours the mixture was filtered. Residual salt was removed from the filtrate by distilling it in vacuo into a receiver flask cooled with acetone/dry ice. The distillate was then distilled through a Vigreux column. 36.2 g (77%) of the title compound were obtained. Boiling point: 126-130°C.

¹H NMR (CDCI₃): 1.82 ppm (s; O-C(CH₃)₃)

¹⁹F NMR (CDCI₃): -10.86 ppm (br. s, CF₃), -7.53 ppm (br. s, CF₃)

1 b) N-Formyl-L-leucine tert-butyl ester The preparation was performed in analogy to W. Duczek et al., Synthesis 1996, 37-38. A solution of 4.04 g (40 mmol) of triethylamine in 10 ml of dichloromethane was added to a solution of 8.94 g (40 mmol) of L-leucine tert-butyl ester hydrochloride and 3.4 g (40 mmol) of cyanomethyl formate in 60 ml of dichloromethane at 0°C. The reaction solution was allowed to warm to room temperature, stirred at room temperature overnight, and then washed twice with saturated NaCI solution. The phases were separated and the organic phase was dried over magnesium sulfate. The residue obtained after filtration and removal of the solvent in vacuo was distilled in vacuo. Yield: 7.5 g (87%). Boiling point: 118°C/2.7 Pa (0.02 torr). ¹H NMR (CDCI3): 0.84 (d, 3H, CH₃), 0.87 (d, 3H, CH₃), 1.36 (s, 9H, C(CH₃)₃), 1.49 (m, 3H, CH, CH₂), 4.51 (m, 1H, N-CH), 6.75 (br. s, 1 H, NH), 8.10 ppm (s, 1 H, CH(O))

1c) tert-Butyl (S)-2-(4,4-bis(trifluoromethyl)-2,5-dioxoimidazolidin-1-yl)-2- (2-methylpropyl)acetate 2.4 g (12.1 mmol) of diphosgene were added to a solution of 2.5 g (11.6 mmol) of N-formyl-L-leucine tert-butyl ester and 2.5 g (24.7 mmol) of triethylamine in 100 ml of dry dichloromethane at -30°C. The reaction solution was allowed to warm to -10°C over the course of 1 hour and was stirred further at this temperature until the reaction was complete. The reaction solution was then washed at room temperature twice with 7% strength sodium hydrogencarbonate solution. The phases were separated and the organic phase was dried over magnesium sulfate. After filtration, the solvent was removed in vacuo, and the residue was taken up in 70 ml of benzene. 3 g

(11.3 mmol) of 2-tert-butoxy-4,4-bis(trifluoromethyl)-1 ,3-oxazabuta-1 ,3-diene in 10 ml of benzene were added dropwise to this solution at room temperature. The reaction solution was heated to 60°C overnight and then benzene was removed in vacuo. Chromatography of the residue over silica gel (eluent: petroleum ether/ethyl acetate = 10/1) resulted in 3.7 g (80%) of the title compound. Melting point: 105-106°C. [α]²⁰ = -24° (c = 1 , CHCl₃).

¹H NMR (CDCI₃): 0.88 (d, 3H, CH₃), 0.92 (d, 3H, CH₃),1.32 (m, 1 H, CH), 1.41 (s, 9H, (CH₃)₃), 1.83 (m, 1 H, CH₂), 2.16 (m, 1H, CH₂), 4.64 (dd, 1H, N-CH), 7.93 ppm (br. s, 1H, NH) ¹⁹F NMR (CDCI₃): 4.8 ppm (m)

¹³C NMR (CDCI₃): 20.95, 23.41 , 25.20, 27.99, 36.68, 53.35, 66.39 (sept, C-CF₃, JC-F = 32.0 Hz), 83.97, 120.49 q (CF₃, J_C-F = 286.5 Hz), 156.18, 160.54, 167.52 ppm

Example 2 (S)-2-(4,4-Bis(trifIuoromethyl)-2,5-dioxoimidazolidin-1-yl)-2-(2-methylpropyl)acetic acid

A solution of 7 g (17.2 mmol) of the compound of example 1c) in 20 ml of dichloromethane were added to a mixture of 30 ml of trifluoroacetic acid and 50 ml of dichloromethane at 10°C, and the reaction mixture was stirred at room temperature for 16 hours. Removal of trifluoroacetic acid and dichloromethane in vacuo resulted in 6.0 g (99%) of the title compound. Melting point: 154-156°C. [α]²² = -23° (c = 2, methanol).

¹H NMR (CD₃OD): 0.92 (m, 6H, (CH₃)₂), 1.41 (m, 1 H, CH), 1.84 (m, 1 H,. CH₂), 2.23 (m, 1 H, CH₂), 4.71 ppm (m, 1 H, N-CH) ¹⁹F NMR (CDCI3): 3.9 ppm (m)

Example 3 tert-Butyl (S)-2-(4,4-bis(trifIuoromethyl)-2,5-dioxoimidazolidin-1-yl)-2- (cyclopropylmethyl)acetate

3a) (S)-β-Cyclopropylalanine tert-butyl ester 3.5 g (27.1 mmol) of (S)-β-cyclopropylalanine were added to a mixture of 50 ml of dioxane and 5 ml of concentrated sulfuric acid (prepared by cautious addition of the acid dropwise to dioxane at 5°C) at room temperature. The solution was transferred into a sealing tube into which 40 ml of isobutylene were condensed at -78°C. The sealed tube was then shaken at room temperature on a shaker for 24 hours. After the sealed tube had been opened (while cooling), the reaction mixture was cautiously introduced into a stirred mixture of 30 ml of triethylamine and 50 ml of water cooled to 0°C. After removal of excess isobutylene, the product was extracted with ether (2 x 50 ml). Drying of the ether phases over magnesium sulfate, filtration and removal of the solvent in vacuo resulted in the crude product (pale yellow oil) which was employed without further purification in the subsequent reaction. Yield 4.2 g (84%). ¹H NMR (CDCI₃): 0.10 (m, 2H, CH₂), 0.49 (m, 2H, CH₂), 0.81 (m, 1 H, CH), 1.25 (br. m, 2H, NH₂), 1.50 (s, 9H, (CH₃)₃), 1.61 (m, 2H, CH₂), 3.41 ppm (dd, 1 H, N-CH) 3b) (S)-N-Formyl-β-cyclopropylalanine tert-butyl ester

A mixture of 10 g (54 mmol) of (S)-β-cyclopropylalanine tert-butyl ester and 4.7 g (55.2 mmol) of cyanomethyl formate in 100 ml of dichloromethane was stirred at room temperature overnight. The residue obtained after removal of the solvent in vacuo was distilled in vacuo. Yield: 8.8 g (76%). Boiling point 120°C/40 Pa (0.3 torr). ¹H NMR (CDCI₃): 0.09 (m, 2H, CH₂), 0.48 (m, 2H, CH₂), 0.65 (m, 1H, CH), 1.47 (s, 9H, (CH₃)₃), 1.69 (m, 2H, CH₂), 4.63 (m, 1H, N-CH), 6.31 (1H, NH), 8.20 ppm (s, 1H, CH(O))

3c) tert-Butyl (S)-2-(4_>4-bis(trifIuoromethyl)-2,5-dioxoimidazolidin-1 -yl)-2-

(cyclopropylmethyl)acetate

2.4 g (12.1 mmol) of diphosgene were added to a solution of 2.5 g (11.7 mmol) of

(S)-N-formyl-β-cycIopropylalanine tert-butyl ester and 2.5 g (24.7 mmol) of triethylamine in 100 ml of dry dichloromethane at -30°C. The reaction solution was allowed to warm to -15°C over the course of 1 hour and was stirred further at this temperature until the reaction was complete. The reaction solution was then washed at room temperature twice with 7% strength sodium hydrogencarbonate solution, and the organic phase was dried over magnesium sulfate. After filtration, the solvent was removed in vacuo, and the residue was taken up in 70 ml of benzene. 3.05 g

(11.5 mmol) of 2-tert-butoxy-4,4-bis(trifluoromethyl)-1 ,3-oxazabuta-1 ,3-diene in 10 ml of benzene were added dropwise at room temperature to this solution. The reaction solution was heated to 60°C overnight and then benzene was removed in vacuo. The residue was chromatographed over silica gel (eluent: petroleum ether/ethyl acetate = 8/1). Yield: 3.7 g (78%). Melting point: 76-77°C. [α]²⁰ = -28° (c = 1 , CHCI₃).

¹H NMR (CDCI₃): 0.08 (m, 2H, CH₂), 0.42 (m, 2H, CH₂), 0.50 (m, 1H, CH), 1.40 (s ,

9H, (CH₃)₃), 2.02 (m, 2H, CH₂), 4.67 (dd, 1 H, N-CH), 7.73 ppm (s, 1 H, NH)

¹⁹F NMR (CDCls): 4.89 ppm (m)

¹³C NMR (CDCI₃): 3.46, 5.21 , 7.76, 27.99, 32.96, 55.41 , 66.48 (sept, C-CF₃, J_C-F = 32.0 Hz), 83.94, 120.49 (q, CF₃, J_C-F = 286.5 Hz), 156.19, 160.55, 166.96 ppm Example 4

(S)-2-(4,4-Bis(trifluoromethyl)-2,5-dioxoimidazolidin-1-yl)-2-(cyclopropylmethyl)acetic acid

A solution of 7 g (17.3 mmol) of the compound of example 3c) in 20 ml of dichloromethane was added to a mixture of 30 ml of trifluoroacetic acid and 50 ml of dichloromethane at 10°C, and the mixture was stirred at room temperature for 16 hours. After removal of trifluoroacetic acid and dichloromethane in vacuo, 5.9 g

(98%) of the title compound were obtained.

Melting point: 123-125°C, [α]²² = -26° (c = 2, methanol).

¹H NMR (de-acetone): 0.40 (m, 2H, CH₂), 0.75 (m, 2H, CH₂), 0.92 (m, 1 H, CH), 2.44

(m, 2H, CH₂), 5.15 (dd, 1H, N-CH), 9.85 ppm (s, 1 H, CO₂H) ¹⁹F NMR (de-acetone): 5.17 ppm (m)

Example 5 (reaction to give the pharmaceutically active ingredient) (S)-3-((S)-2-(4,4-Bis(trifluoromethyl)-3-(4-(3-(2-methylphenyl)ureido)- 3-methoxybenzyl)-2,5-dioxoimidazolidin-1-yl)-2-(cyclopropylmethyl)acetylamino)- 3-phenylpropionic acid

5a) 4-(3-(2-Methylphenyl)ureido)-3-methoxybenzyl alcohol

15 g (81.8 mmol) of 3-methoxy-4-nitro benzyl alcohol were hydrogenated in 500 ml of methyl tert-butyl ether over 1.3 g of palladium/carbon (10%; 50% water) while cooling in ice. After hydrogen uptake had ceased, the catalyst was filtered off, and 10.14 ml (81.8 mmol) of 2-methyIphenyl isocyanate were added to the stirred filtrate over the course of 30 minutes. The reaction mixture was left to stand overnight, and the precipitated solid was filtered off with suction and washed with methyl tert-butyl ether. Yield: 20.5 g (88%).

5b) 4-(3-(2-Methylphenyl)ureido)-3-methoxybenzyl chloride 7.65 ml (104.8 mmol) of thionyl chloride were added dropwise to a suspension of 15 g (52.4 mmol) of the compound of example 5a) in 300 ml of dichloromethane while cooling in ice. The reaction mixture was then stirred at room temperature for 3 hours, left to stand overnight and poured into 1000 ml of heptane. The heptane was decanted off from the oil which had separated out, the residue was again suspended in heptane, and the heptane was decanted off. This procedure was repeated twice more. The residue was then dissolved in dichloromethane and poured into 800 ml of ice-cold diisopropyl ether. The mixture was then stirred while cooling in ice for 2 hours, and the product was filtered off with suction, washed with diisopropyl ether and dried over phosphorus pentoxide. Yield: 12 g (75%).

5c) (S)-2-(4,4-Bis(trifluoromethyl)-3-(4-(3-(2-methylphenyl)ureido)-3-methoxybenzyl)- 2,5-dioxoimidazolidin-1 -yl)-2-(cyclopropylmethyl)acetic acid 3.2 ml of an n-butyllithium solution (2.5 M in hexane) were added to a solution of 1.39 g (4 mmol) of the compound of example 4) in 40 ml of absolute tetrahydrofuran (THF) under argon at -40°C. The reaction mixture was allowed to warm to 0°C while stirring, a solution of 2.43 g (8 mmol) of 4-(3-(2-methylphenyl)ureido)-3- methoxybenzyl chloride in 20 ml of absolute THF was added, and the reaction mixture was stirred at room temperature for 3 hours. 20 ml of 1 N hydrochloric acid were added and THF was removed in vacuo. The aqueous phase was extracted twice with methyl tert-butyl ether. The combined organic phases were dried over sodium sulfate and, after filtration, concentrated in vacuo. The residue was purified by preparative HPLC. Concentration of the product fractions and freeze drying resulted in 1.41 g (57%) of the title compound.

5d) Ethyl (S)-3-((S)-2-(4,4-bis(trifluoromethyl)-3-(4-(3-(2-methylphenyl)ureido)- 3-methoxybenzyl)-2,5-dioxoimidazolidin-1-yl)-2-(cyclopropylmethyl)acetylamino)- 3-phenylpropionate

748 mg (2.28 mmol) of TOTU (O-((cyano(ethoxycarbonyl)methylene)amino)- N,N,N',N'-tetramethyluronium tetrafluoroborate) and 368 μl of N,N-diisopropyl- ethylamine were added to a solution of 1.41 g (2.28 mmol) of the compound of example 5c) and 442 mg (2.28 mmol) of ethyl (S)-3-amino-3-phenylpropionate in 20 ml of absolute dimethylformamide (DMF) at 0°C. After stirring at room temperature for 1 hour, the DMF was removed in vacuo, the residue was taken up in ethyl acetate, and the ethyl acetate solution was washed successively with an aqueous KHSO₄/K₂SO₄ solution, a saturated NaHCO₃ solution and water. The organic phase was dried over sodium sulfate and filtered. The solvent was then removed in vacuo, and the residue was chromatographed over silica gel with heptane/ethyl acetate (3/2). Concentration of the product fractions resulted in 1.48 g (82%) of the title compound.

5e) (S)-3-((S)-2-(4,4-Bis(trifluoromethyl)-3-(4-(3-(2-methylphenyl)ureido)-3-methoxy- benzyl)-2,5-dioxoimidazolidin-1-yl)-2-(cyclopropylmethyl)acetylamino)-

3-phenylpropionic acid

A solution of 1.46 g (1.84 mmol) of the compound of example 5d) in 40 ml of N-methyl-2-pyrroiidone and 20 ml of 6N hydrochloric acid was heated at 60°C for 6 hours. After cooling to room temperature, the reaction mixture was poured into 300 ml of water, and the precipitate was filtered off with suction, washed with water and dried over phosphorus pentoxide. The crude product was chromatographed twice over silica gel (eluent: dichloromethane/methanol/acetic acid/water = 95/5/0.5/0.5). After concentration of the product fractions, the residue was taken up in dichloromethane, and the organic phase was washed with water and dried over sodium sulfate. Filtration, removal of the solvent in vacuo and freeze drying resulted in 1.19 g (85%) of the title compound. ES(+)-MS: 764.2 (M+H)⁺

Claims

Patent claims

1. A hydantoin of the formula I

in which R is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative which is obtained formally by removing an NH₂ group from an amino carboxylic acid or an amino carboxylic acid derivative, and the salts thereof.

2. A hydantoin of the formula I as claimed in claim 1 , in which R is the residue of an α-amino carboxylic acid, of an α-amino carboxylic acid derivative, of a β-amino carboxylic acid, of a β-amino carboxylic acid derivative, of a y-amino carboxylic acid, of a z-amino carboxylic acid derivative, of an aromatic amino carboxylic acid or of a derivative of an aromatic amino carboxylic acid, and the salts thereof.

3. A hydantoin of the formula I as claimed in claims 1 and/or 2, which is a compound of the formula le

or a compound in which the carboxylic acid group in the formula le and/or other carboxylic acid groups are converted into carboxylic acid derivatives, where R¹ is hydrogen or an unsubstituted or substituted residue from the series (Cι-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₃-C₇)-cycloalkyl, (C₃-C₇)-cycloalkyI-(C₁-C₄)-alkyl, (C₆-Cι₂)-aryl, (C₆-Cι₂)-aryl-(Cι-C₄)-alkyl, heteroaryl and heteroaryl-(Cι-C )-alkyl, and the salts thereof.

4. A hydantoin of the formula I as claimed in one or more of claims 1 to 3, which is a compound of the formula le

or a compound in which the carboxylic acid group in the formula le is converted into a carboxylic acid derivative, where R¹ is (C-i-CβJ-alkyl, (C₃-C₇)-cycloaIkyl or (C₃-C₇)-cycloalkyl-(Cι-C₄)-alkyl, and the salts thereof.

5. A hydantoin of the formula I as claimed in one or more of claims 1 to 4, which is a compound of the formula le

or a compound in which the carboxylic acid group in the formula le is converted into a carboxylic acid derivative, where R¹ is isobutyl or cyclopropylmethyl, and the salts thereof.

6. A hydantoin of the formula I as claimed in claims 4 and/or 5, wherein the carbon atom carrying the R¹ residue has the S configuration.

7. A hydantoin of the formula I as claimed in one or more of claims 1 to 6, wherein the carboxylic acid derivative is a (C-ι-C₆)-aIkyl carboxylate.

8. A process for preparing a hydantoin of the formula I as claimed in one or more of claims 1 to 7, which comprises reacting the compound of the formula II with a compound of the formula III

III

II

where the residue R¹ in the formula III has the meanings stated in claims 1 to 7 for the residue R in formula I, but where free carboxylic acid groups are present in the compounds of the formula III in esterified form.

9. The use of a hydantoin as claimed in one or more of claims 1 to 7 as intermediate in the preparation of a pharmaceutically active ingredient.

10. A process for preparing a pharmaceutically active ingredient comprising a 2,5-dioxo-4,4-bis(trifluoromethyl)imidazolidine ring, which comprises reacting a compound of the formula I as claimed in one or more of claims 1 to 7 at a functional group in the residue R with another synthon.